Opportunistic Infections: Clinical Trials

8 trials for Opportunistic Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 terminated, 1 unknown, 1 withdrawn. 8 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 48Completed 5, Terminated 1, Unknown 1, Withdrawn 1

Follow Opportunistic Infections: new trials by email Literature Review of Opportunistic Infections trials Research Report on Opportunistic Infections

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Inflammation and Co-Infections in D²EFT
NRTIs, Darunavir, Ritonavir - HIV-infection/Aids, Human Herpesvirus 4 Infections
Phase 4WithdrawnKirby Institute2021-02-012020-11-10
Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria
Cotrimoxazole, Placebo - HIV-1-infection, Pneumocystis Pneumonia
Phase 4CompletedUniversity of Bergen5372017-03-302019-10-02
Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda
cotrimoxazole, Placebo - HIV Infections
Phase 4UnknownMRC/UVRI and LSHTM Uganda Research Unit16502008-06-012008-06-05
ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients
MCT/LCT (1:1), MCT/LCT/omega-3 (5:4:1) - Critical Illness
Phase 4TerminatedB. Braun Medical SA2122006-11-012013-07-19
Antiretroviral Therapy for Advanced HIV Disease in South Africa
Zidovudine, Stavudine, Didanosine - HIV
Phase 4CompletedNational Institutes of Health Clinical Center (CC)17712004-01-012013-05-21
When to Start Anti-HIV Drugs in Patients With Opportunistic Infections
Emtricitabine/tenofovir disoproxil fumarate, Lopinavir/ritonavir, Stavudine - HIV Infections, AIDS-Related Opportunistic Infections
Phase 4CompletedNational Institute of Allergy and Infectious Diseases (NIAID)2832003-03-012014-10-15
Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance
Cotrimoxazole (trimethoprim sulfamethoxazole) - HIV, Malaria
Phase 4CompletedCenters for Disease Control and Prevention14782002-02-012005-12-13
A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush
Fluconazole - Candidiasis, Oral, HIV Infections
Phase 4CompletedNational Institute of Allergy and Infectious Diseases (NIAID)9482021-10-29

Narrower conditions

Acquired Immunodeficiency Syndrome (3)  ·  HIV Infections (3)  ·  AIDS-Related Opportunistic Infections (2)  ·  Candidiasis, Oral (1)  ·  Coinfection (1)  ·  Critical Illness (1)  ·  Cytomegalovirus Infections (1)  ·  Diarrhea (1)  ·  Disease Progression (1)  ·  Epstein-Barr Virus Infections (1)  ·  Escherichia coli Infections (1)  ·  Hyperphagia (1)  ·  Inflammation (1)  ·  Malaria (1)

Broader conditions

Infections (8)  ·  Blood-Borne Infections (5)  ·  Communicable Diseases (5)  ·  Genital Diseases (5)  ·  Immune System Diseases (5)  ·  Immunologic Deficiency Syndromes (5)  ·  Lentivirus Infections (5)  ·  RNA Virus Infections (5)  ·  Retroviridae Infections (5)  ·  Sexually Transmitted Diseases (5)  ·  Sexually Transmitted Diseases, Viral (5)  ·  Urogenital Diseases (5)  ·  Virus Diseases (5)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Bacterial Infections and Mycoses (3)

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination (3)  ·  Lopinavir (2)  ·  Stavudine (2)  ·  Darunavir (1)  ·  Didanosine (1)  ·  Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1)  ·  Fluconazole (1)  ·  Lamivudine (1)  ·  Nucleosides (1)  ·  Ritonavir (1)  ·  Zidovudine (1)  ·  dolutegravir (1)  ·  efavirenz (1)  ·  lopinavir-ritonavir drug combination (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  B. Braun Medical SA (1)  ·  Centers for Disease Control and Prevention (1)  ·  Kirby Institute (1)  ·  MRC/UVRI and LSHTM Uganda Research Unit (1)  ·  National Institutes of Health Clinical Center (CC) (1)  ·  University of Bergen (1)

Countries

Puerto Rico (2)  ·  South Africa (2)  ·  United States (2)  ·  Kenya (1)  ·  Spain (1)  ·  Tanzania (1)  ·  Uganda (1)

Top investigators

Alfonso Bonet Saris, MD_Study Coordinator (1)  ·  Andrew R. Zolopa, MD (1)  ·  Andrew Ratsela, MD (1)  ·  George Miiro, MSc, MBChB (1)  ·  Heiner Grosskurth, PhD, MD (1)  ·  Joel Manyahi, MD (1)  ·  Mark Polizzotto, MD, PhD (1)  ·  Mary J Hamel, M.D. (1)  ·  Michael Polis, MD (1)  ·  Mitchell Goldman (1)  ·  Paula Munderi, MRCP, MBChB (1)  ·  Scott G. Filler (1)  ·  Teodoro Grau Carmona, MD_Study Coordinator (1)

Results publications

PMID 10218526, PMID 10219064, PMID 11172138, PMID 11188837, PMID 12594647, PMID 15577626, PMID 16371882, PMID 19440326, PMID 20617176, PMID 20942650, PMID 21126955, PMID 21716078, PMID 22448211, PMID 32653726, PMID 33586013, PMID 36803640

NIH funding

2005 (1)